"x"
"c(\"Other\", \"Other\", \"Drug\", \"Device\", \"Diagnostic Test\", \"Genetic\", \"Other\", \"Other\", \"Other\", \"Other\", \"Diagnostic Test\")"
"c(\"LDH serum level\", \"measuring hemodynamic parameters heart beat to heart beat during single-frequency exposure\", \"Xihuang Capsules\", \"Low intensity amplitude-moduled electromagnetic fields\", \"\\"Epi proColon 2.0 CE\\" test from Epigenomics, Inc (Berlin, Germany)\", \"DNA methylation\", \"Regression of fibrosis\", \"Specific risk factors related to hepatocellular carcinoma\", \"Cirrhosis with HCC\", \"Cirrhosis without HCC\", \"5hmC profile in plasma cell-free DNA after liver resection\")"
"c(\"Blood sample to measure LDH as a predictor of Hepatocellular carcinoma treatment outcome\", \"This study aims to create a method for non-invasive diagnosis of biofeedback effect exposure to LEEF modulated to specific frequencies in individuals exposed to hepatocellular carcinoma -specific frequencies in increasing sequential manner, frequency to frequency in patients with advanced hepatocellular carcinoma and healthy individuals.\nPatients with advanced hepatocellular carcinoma will be exposed to specific LEEF-modulated frequencies (3 to 10 Hz difference) to identify the optimal frequency associated with greater response to the biofeedback effect in patients with advanced hepatocellular carcinoma.\", 
\"In two weeks after hepatectomy, Xihuang Capsules group received Xihuang Capsules (2 g, bid), Continuously taking to cancer recurrence or death.\", \"Patients in each arm will be exposed to 30 min of amplitude-moduled low intensity electromagnetic fields only one time.\", \"The mSEPT9 assay consists of DNA extraction from plasma, bisulfite conversion of DNA, purification of bis-DNA, and real-time PCR.\", \"DNA methylation will be measured by real time polymerase chain reaction\", \"Regression of fibrosis will be defined by assessing yearly evolution of noninvasive markers in patients who received antiviral therapy before start of the study, and by comparing baseline markers before start of antiviral therapy to those on subsequent yearly visits in patients prospective recruited (>50% of cases).\", 
\"Such as: family history of liver cancer; body mass index; alcohol, smoking and recreational drug use status; dietary habits, including use of caffeinated drinks; comorbidities such as type 2 diabetes mellitus; use of medications for other chronic diseases such as statins and angiotensin-converting enzyme inhibitors.\", \"Cirrhosis with Hepatocellular Carcinoma\", \"Cirrhosis without Hepatocellular Carcinoma\", \"Peripheral blood is drawn every 3 months after liver resection for 5hmC test (Time frame: 2 years or until tumor recurrence).\"
)"
"c(\"Group A\", \"Autonomic response\", \"Xihuang Capsules group\", \"hepatitis\", \"HCC-free cirrhotic patients\", \"Healthy controls\", \"Regression of fibrosis\", \"Regression of fibrosis\", \"Cirrhosis with HCC\", \"Cirrhosis without HCC\", \"serum AFP negative HCC patients\")"
"c(\"Group B\", NA, NA, \"hepatocellular carcinoma patients\", \"HCC-positive cirrhotic patients\", \"Hepatic cirrhosis\", NA, NA, NA, NA, NA)"
"c(\"Group C\", NA, NA, NA, NA, \"Hepatocellular carcinoma\", NA, NA, NA, NA, NA)"
"c(\"Group D\", NA, NA, NA, NA, NA, NA, NA, NA, NA, NA)"
"c(\"NCT03338166\", \"NCT03448757\", \"NCT02399033\", \"NCT01641276\", \"NCT03311152\", \"NCT04220151\", \"NCT01831037\", \"NCT01831037\", \"NCT03162198\", \"NCT03162198\", \"NCT03493763\")"
"c(NA, NA, \"Wangbang Pharmaceutical Xihuang Capsules\", \"TheraBionic\", \"Plasma mSEPT9 test\", NA, \"FibroTest, FibroSure, FibroScan (transient elastography)\", NA, NA, NA, NA)"
"c(NA, NA, NA, \"OncoBionic P1\", NA, NA, NA, NA, NA, NA, NA)"
